Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives Average Rating of "Hold" from Brokerages

Key Points

• Eton Pharmaceuticals, Inc. has an average consensus rating of "Hold" among five brokerages, with one sell recommendation, one hold, and three buy ratings.
• The company's recent stock performance shows a market cap of $561.34 million and a PE ratio of -130.81, with a 1-year high of $23.00.
• CFO James R. Gruber sold 2,631 shares at an average price of $16.02, indicating a decrease in his position, which raises potential concerns about insider confidence.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) has been assigned a consensus rating of "Hold" from the five ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $29.6667.

A number of brokerages have recently weighed in on ETON. Wall Street Zen raised Eton Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday, September 26th. Zacks Research raised Eton Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Eton Pharmaceuticals in a research note on Wednesday.

Insider Activity

In related news, CFO James R. Gruber sold 2,631 shares of the company's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $16.02, for a total value of $42,148.62. Following the completion of the sale, the chief financial officer directly owned 204,753 shares of the company's stock, valued at $3,280,143.06. This represents a 1.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 16.03% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of large investors have recently modified their holdings of ETON. Man Group plc grew its holdings in Eton Pharmaceuticals by 6.0% during the 2nd quarter. Man Group plc now owns 23,754 shares of the company's stock valued at $338,000 after buying an additional 1,350 shares during the last quarter. AlphaQuest LLC grew its holdings in Eton Pharmaceuticals by 44.4% during the 2nd quarter. AlphaQuest LLC now owns 5,948 shares of the company's stock valued at $85,000 after buying an additional 1,830 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new stake in Eton Pharmaceuticals during the 2nd quarter valued at $37,000. Legal & General Group Plc acquired a new stake in Eton Pharmaceuticals during the 2nd quarter valued at $41,000. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of Eton Pharmaceuticals by 33.1% during the second quarter. Envestnet Asset Management Inc. now owns 23,050 shares of the company's stock worth $328,000 after purchasing an additional 5,734 shares during the last quarter. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON opened at $20.93 on Thursday. The company has a market cap of $561.34 million, a PE ratio of -130.81 and a beta of 1.16. The stock's 50 day simple moving average is $17.85 and its 200-day simple moving average is $16.21. Eton Pharmaceuticals has a 1-year low of $7.25 and a 1-year high of $23.00. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.77 and a quick ratio of 1.16.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.09). Eton Pharmaceuticals had a negative return on equity of 0.73% and a negative net margin of 7.10%.The company had revenue of $18.93 million for the quarter, compared to analysts' expectations of $16.71 million. As a group, equities research analysts anticipate that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.